Taysha Gene Therapies, Inc. (TSHA) Stock

Understand Taysha Gene Therapies, Inc.: how it makes money

Taysha Gene Therapies develops and aims to commercialize adeno-associated virus (AAV) gene therapies for monogenic central nervous system diseases, building its pipeline around programs such as TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, and TSHA-101.

Its profit model is tied to whether its AAV gene therapy candidates show clinically meaningful effects in trials, because the company is focused on developing and commercializing those therapies for specific monogenic CNS diseases.

Business quality (Weak): This is a clinical-stage gene therapy company with multiple programs and reported operating losses, where the most decision-relevant signals are trial response rates and ongoing patient dosing in its studies.

Bull case

• High-dose durability signal in Part A: The high-dose cohort response rate is reported as 100.0% at nine months post-treatment.
• High-dose response at six months: The high-dose cohort response rate is reported as 83.0% at six months post-treatment.
• Active patient dosing and assessment in Part A: Patients Treated in Part A of the REVEAL Phase 1/2 Trials is reported as 12.0 (count), and the number of patients treated assessed in the clinical data presentation is reported as 10.0 (count).

Bear case

• No reported revenue yet and large operating losses: For the period ending 2025-06-30, reported revenue is 0.0B and operating margin is -1347.1.
• Small treated cohorts: High-Dose Cohort Patients Treated is reported as 4.0 (count), and Low-Dose Cohort Patients Treated is also reported as 4.0 (count), which can make results more sensitive to individual patient outcomes.
• Key effectiveness is probabilistic and threshold-dependent: The likelihood of the primary endpoint occurring without treatment is reported as 6.7 (percent), and a Minimum Threshold Responder Rate of 33.0 (percent) is also cited, implying the interpretation depends on meeting study-defined thresholds.

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

• ADMA Biologics, Inc. (ADMA)
• Recursion Pharmaceuticals, Inc. (RXRX)
• Maze Therapeutics, Inc. (MAZE)
• Vir Biotechnology, Inc. (VIR)
• Novavax, Inc. (NVAX)
• Cullinan Therapeutics, Inc. (CGEM)
• Replimune Group, Inc. (REPL)
• Monte Rosa Therapeutics, Inc. (GLUE)